Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner


rss_Pharma.jpg...see all
Stem Cell Technologies: World Market Outlook 2011-2021

Stem Cell Technologies: World Market Outlook 2011-2021

  • Publication date: 10/05/2011
  • Number of Pages: 137
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

- how you can discover the commercial opportunities there

How will the stem cells market develop this decade? Our new report shows you that emerging industry and market's revenue potential from 2011 to 2021.

This report covers stem cells in therapeutic applications: technologies, products and services. You will assess events, opportunities and activities shaping that industry. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our new study shows you revenue prospects for stem cells at total world, submarket and product levels to 2021. What activities will expand that market from 2011 to 2021? Our work helps you to understand the stem cells industry and market.

When will significant numbers of stem cell therapies be launched? Which disease areas hold the greatest potential for stem cell therapies? We show you which markets will provide the best opportunities for research, product development and business from 2011 onwards.

What are the most crucial drivers and restraints in the development of stem cell therapies? How significant are other uses for stem cells, beyond therapy? Our report provides data and answers you need.

We help you to assess the stem cell industry and market's strengths, weaknesses, trends and revenue opportunities to 2021. You will see where stem cell technologies are heading.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Industry and market analysis to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review and analysis of companies, technologies and regulations, as well as opinions from our survey.

We include 66 tables and charts and a research interview (shown in the accompanying lists). In particular, we cover research and applications involving pluripotent and multipotent stem cells for human use.

Stem Cell Technologies: World Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the stem cells industry and market - especially our revenue forecasts to 2021
• You will discover revenue predictions for the overall market from 2011 to 2021
• You will receive market forecasts for the main subsectors - stem cell therapies, stem cell services, cord blood banking and bone marrow transplants
• You will discover revenue prospects to 2021 for the leading stem cell product
• You will find out which disease areas are receiving the most attention from researchers and how soon treatments can be launched
• You will receive analysis of the uses of stem cells and discussion of the commercial prospects for their use beyond therapy
• You will review stem cell regulations, research and related activities in the US, Japan, Germany, France, Spain, the UK, Italy, China, India, Israel and South Korea
• You will identify the leading companies in stem cell therapies, stem cell services and cord blood banking - we discuss the activities of over 40 companies there
• You will investigate competition and opportunities influencing the industry and market
• You will see what will stimulate and restrain the industry and market from 2011
• You will analyse opportunities and challenges for established companies and those seeking to enter the stem cells market from 2011
• You will review the technologies in development, assessing stem cell R&D potential
• You will view opinion from our industry survey.

That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for stem cell technologies.

Order our report now to gain industry and market information you need

Our report can benefit everybody interested in products, research, services and market analysis for stem cell technologies. We give predictions and answers you need. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Executive Summary
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.3.1 Speculative Aspects of Assessing the Stem Cell Field

2. Introduction to Stem Cell Technologies
2.1 What Are Stem Cells?
2.2 How Are Stem Cells Classified?
2.2.1 Totipotency
2.2.2 Pluripotency
2.2.3 Multipotency
2.2.4 Oligopotency
2.2.5 Unipotency
2.3 Where Do Stem Cells Come From?
2.3.1 Embryonic Stem Cells Abortion Debates, IVF and Embryonic Stem Cells Harvesting Human Eggs
2.3.2 Adult Stem Cells
2.3.3 Umbilical Cord Blood Stem Cells

3. The Global Stem Cells Market 2011-2021
3.1 Defining the Stem Cells Market
3.2 Growth in the Stem Cells Market 2011-2021
3.3 Stem Cell Therapies
3.3.1 Stem Cell Therapies Market Forecast 2011-2021
3.3.2 Stem Cells and Bone Regeneration Osteocel Plus (NuVasive) Osteocel Plus Sales Forecast 2011-2021 Other Orthopaedic Stem Cell Products
3.3.3 Stem Cells and Regenerative Medicine
3.3.4 Stem Cell Cosmetics
3.3.5 Unregulated Stem Cell Therapies
3.4 Bone Marrow Transplants
3.4.1 Graft-versus-Host Disease and Host-versus-Graft Disease
3.4.2 Bone Marrow Transplants and Medicare Coverage
3.4.3 Private Bone Marrow Transplant Forecast 2011-2021
3.4.4 Peripheral Blood Stem Cell Transplants
3.4.5 Cord Blood Stem Cell Transplants
3.5 Stem Cell Services
3.5.1 Disease Modelling
3.5.2 Toxicity Screening
3.5.3 Stem Cell Services Market Forecast 2011-2021
3.6 Blood Banking
3.6.1 Private vs. Public Blood Banks
3.6.2 Arguments For and Against Cord Blood Banking
3.6.3 Private Cord Blood Banking Market Forecast 2011-2021

4. Companies Driving the Stem Cells Market
4.1 Leading Companies Developing Stem Cell Therapies
4.1.1 Aastrom Biosciences
4.1.2 Advanced Cell Technology
4.1.3 AmStem
4.1.4 Athersys
4.1.5 BioHeart
4.1.6 BrainStorm Cell Therapeutics
4.1.7 Cytori Therapeutics
4.1.8 Gamida Cell
4.1.9 Geron Geron and GE Healthcare
4.1.10 MediStem Laboratories
4.1.11 Mesoblast
4.1.12 Neostem
4.1.13 Neuralstem
4.1.14 Opexa Therapeutics Tovaxin
4.1.15 Osiris Therapeutics Prochymal Chondrogen
4.1.16 Pluristem Therapeutics
4.1.17 Reliance Life Sciences
4.1.18 ReNeuron
4.1.19 StemCells
4.1.20 TCA Cellular Therapy
4.2 Some Companies Offering Stem Cell Services
4.2.1 Axiogenesis
4.2.2 BioTime CellCure Neurosciences
4.2.3 CellCyte Genetics
4.2.4 Cellular Dynamics International
4.2.5 International Stem Cell Corp
4.2.6 MultiCell Technologies
4.2.7 Regenetech
4.2.8 Stem Cell Innovations
4.2.9 Stemgent
4.2.10 Thermo Fisher Scientific/HyClone
4.2.11 ViaCyte
4.2.12 Vitro Biopharma
4.3 Selected Private Cord Blood Banks
4.3.1 Biogenea-Cellgenea
4.3.2 China Cord Blood Corp
4.3.3 Cord Blood America
4.3.4 Cryo-Cell International
4.3.5 Cryo-Save
4.3.6 LifebankUSA
4.3.7 Thermogenesis
4.3.8 ViaCord

5. Issues Affecting the Stem Cell Technologies Market 2011-2021
5.1 SWOT Chart for the Stem Cells Market 2011-2021
5.2 Strengths
5.2.1 Stem Cell Therapies Already Have a Number of Applications
5.2.2 Stem Cells Have Vast Therapeutic Potential
5.2.3 Stem Cells Have Uses Beyond Therapy
5.2.4 Strength in Numbers
5.2.5 Strong Government Support for Stem Cells
5.3 Weaknesses
5.3.1 The Research Field is Fragmented
5.3.2 A Complex Intellectual Property Environment
5.3.3 Research Relies Too Heavily on Government Funding
5.3.4 Difficulties in Scaling Up
5.3.5 Neither Autologous nor Allogeneic Therapies Are Perfect Yet Autologous Therapies Allogeneic Therapies Incompatibility with the Existing Pharmaceutical Model?
5.4 Opportunities
5.4.1 Leading Pharma Companies Investing in Stem Cell Research
5.4.2 The Potential of iPSCs Transdifferentiation
5.4.3 Philanthropy May Prove a Good Source of Funding
5.4.4 Asia Offers Dynamic Opportunities South Korea Israel
5.4.5 The First New Therapies Launched Will Drive Market Growth
5.5 Threats
5.5.1 Some Companies Will Fail Case Study: Garnet BioTherapeutics
5.5.2 Maintaining Public Support is Vital but Difficult
5.5.3 Difficulties with Animal Models
5.5.4 There Remains Uncertainty in the Future Pathway of US Research
5.5.5 Rapid Progress Makes Certain Discoveries Obsolete

6. Therapeutic Applications for Stem Cell Therapies 2011-2021
6.1 Near-Term Indications
6.1.1 Cancer Cancer Stem Cells
6.1.2 Immune Disorders
6.1.3 Eye Diseases
6.1.4 Orthopaedics
6.1.5 Diabetes
6.2 Cardiovascular Diseases
6.3 Central Nervous System (CNS) Diseases
6.3.1 Amyotrophic Lateral Sclerosis (ALS)
6.3.2 Multiple Sclerosis Pelizaeus-Merzbacher Disease (PMD)
6.3.3 Alzheimer's Disease
6.3.4 Cerebral Palsy
6.3.5 Parkinson's Disease
6.3.6 Spinal Cord Injury
6.4 Growing Organs

7. Regional Analysis of the Stem Cells Market 2011-2021
7.1 Global Spread of Stem Cell Research
7.2 The United States
7.2.1 US Market Drivers and Restraints, 2011-2021
7.2.2 California Institute of Regenerative Medicine (CIRM)
7.3 Japan
7.3.1 Commercial Aspects of Stem Cells in Japan
7.4 Europe
7.4.1 The UK
7.4.2 Spain
7.4.3 Germany
7.4.4 France
7.4.5 Italy
7.5 China
7.6 India

8. Research Interview
8.1 Yael Margolin, President and CEO, Gamida Cell
8.1.1 Challenges in Developing Stem Cell Therapies
8.1.2 Israel's Strength in Stem Cell Research
8.1.3 Public Perception of Stem Cell Therapies
8.1.4 Therapeutic Targets and Gamida Cell's Stem Cell Therapies
8.1.5 Umbilical Cord Blood Stem Cells

9. Conclusions
9.1The Stem Cells Market is Currently Small
9.2 Market Growth Will be Dependent on Stem Cell Therapies
9.3 Induced Pluripotent Stem Cells Represent a Strong Market Opportunity
9.4 Stem Cell Therapies Will be Used in Many Disease Areas
9.5 Concluding Remarks

List of Tables
Table 1.1 Currency Exchange Rates, 2009-2010
Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
Table 3.1 Global Stem Cell Market, 2010
Table 3.2 Global Stem Cells Market: Forecast, 2010-2021
Table 3.3 Global Stem Cells Market: Drivers and Restraints, 2011-2021
Table 3.4 Selected Uses for Stem Cells Therapies, 2011
Table 3.5 Stem Cell Therapies Market: Drivers and Restraints, 2011-2021
Table 3.6 Osteocel Plus Sales Forecast, 2010-2021
Table 3.7 Companies Not Considered Part of the Stem Cell Market in this Report
Table 3.8 Sources of Stem Cells for Bone Marrow Transplants
Table 3.9 Medicare Coverage for Bone Marrow Transplants, 2011
Table 3.10 Bone Marrow Transplants Market: Drivers and Restraints, 2011-2021
Table 3.11 Stem Cell Services Market: Drivers and Restraints, 2011-2021
Table 3.12 Costs of Various Private Cord Blood Banks Worldwide, 2011
Table 3.13 Cord Blood Banking Market: Drivers and Restraints, 2011-2021
Table 4.1 Selected Stem Cell Therapy Companies and Their Leading Products, 2011
Table 4.2 Histostem's Leading Clinical Investigations, 2011
Table 4.3 MultiStem Pipeline, 2011
Table 4.4 Gamida Cell's Stem Cell Therapy Pipeline, 2011
Table 4.5 Geron's Stem Cell Therapy Pipeline, 2011
Table 4.6 Clinical Progress of GRN-1632, 2011
Table 4.7 Osiris Therapeutics Stem Cell Pipeline, December 2010
Table 4.8 TCA Cellular Therapy Clinical Progress, 2011
Table 4.9 Selected Stem Cell Services Companies, 2011
Table 4.10 Selected Private Cord Blood Banks, 2011
Table 4.11 China Cord Blood Corp Revenue and Subscribers, 2009-2010
Table 4.12 Cryo-Cell International Revenue, 2009-2010
Table 4.13 Cryo-Save Revenue and Operating Profit, 2009-2010
Table 4.14 Cryo-Save Revenue by Region, 2010
Table 5.1 SWOT Analysis of the Market, 2011-2021
Table 5.2 NIH Human Stem Cell Research Funding, 2002-2010
Table 6.1 Selected Examples of Stem Cell Research, 2010-2011
Table 6.2 Stem Cell Clinical Trials by Indication, 2011
Table 6.3 Neurodegenerative Diseases: Stem Cell Clinical Trials by Indication, 2011
Table 7.1 Stem Cell Clinical Trials by Country, 2011
Table 7.2 NIH Stem Cell Research Funding, 2002-2010
Table 7.3 CIRM Funding by Disease, 2004-2011
Table 7.4 Indian Stem Cell Clinical Trials Conducted, 2011
Table 9.1 Stem Cells Market Value and Market Shares, 2010, 2016 and 2021

List of Figures
Figure 2.1 The Early History of Stem Cell Discovery and Development
Figure 3.1 Global Stem Cell Market, 2010
Figure 3.2 Global Stem Cells Market Forecast, 2010-2021
Figure 3.3 Stem Cell Therapies Market Forecast, 2010-2021
Figure 3.4 Osteocel Plus Sales Forecast, 2010-2021
Figure 3.5 Private Bone Marrow Transplant Market Forecast, 2011-2021
Figure 3.6 Stem Cell Services Market Forecast, 2010-2021
Figure 3.7 Twenty Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011
Figure 3.8 Cord Blood Banking Market Forecast, 2010-2021
Figure 4.1 MultiStem Key Events, 2006-2011
Figure 4.2 China Cord Blood Corp Revenue and Subscribers, 2009-2010
Figure 4.3 Cryo-Cell International Revenue, 2009-2010
Figure 4.4 Cryo-Save Revenue and Operating Profit, 2009-2010
Figure 4.5 Cryo-Save Revenue by Region, 2010
Figure 5.1 NIH Human Stem Cell Research Funding, 2002-2010
Figure 5.2 Pfizer's Stem Cell Collaborations, 2008-2011
Figure 6.1 Stem Cell Clinical Trials for Cancer by Phase, 2011
Figure 6.2 Neurodegenerative Diseases: Stem Cell Clinical Trials by Indication, 2011
Figure 6.3 Five Stages of Parkinson's Disease
Figure 7.1 Stem Cell Clinical Trials by Country, 2011
Figure 7.2 NIH Stem Cell Research Funding, 2002-2010
Figure 7.3 Key Events in the US Federal Funding of hESC Research Lawsuit, 2009-2010
Figure 7.4 CIRM Funding by Disease, 2004-2011
Figure 7.5 Example of the UK Stem Cell Therapy Regulatory Pathway, 2011
Figure 9.1 Stem Cells Market by Sector, 2016
Figure 9.2 Stem Cells Market by Sector, 2021

Companies Listed

Aastrom Biosciences
Advanced Cell Technology
Agence Nationale de la Recherche [France]
Alliance for Regenerative Medicine
AlphaTec Spine
American Heart Association
AmStem International
Angioblast Systems
AXM Pharma
Beike Biotechnology
BioMimetic Therapeutics
Boston Biomedical
BrainStorm Cell Therapeutics
California Institute of Regenerative Medicine (CIRM)
Care Quality Commission
Catalan Institute for Research and Advanced Studies
Cell Cure Neurosciences
CellCyte Genetics
Cellular Dynamics International
Cha General Hospital [South Korea]
China Cord Blood Corp
Cleveland Clinic
Columbia University
CorCell Companies
Cord Blood America
Cryo-Cell International
Cryo-Cell Mexico
Cytori Therapeutics
Denali Ventures
Department for Health and Human Services [US]
Department of Biotechnology [India]
Department of Defense [US]
Department of Health [UK]
Drugs Controller of India
Duke University Medical Center
Ebryome Sciences (now ReCyte Therapeutics)
EMA Committee for Orphan Medicinal Products
Emerging Healthcare Solutions
ES Cell International
European Court of Justice
European Medicines Agency (EMA)
Fate Therapeutics
FDA Center for Biologics Evaluation and Research [US]
Food and Drug Administration (FDA) [US]
French National Assembly
Gamida Cell
Garnet BioTherapeutics
GE Healthcare
Gene Therapy Advisory Committee [UK]
General BioTechnology
Georgetown University Medical Center
Hadassah Hospital [Israel]
Harvard Stem Cell Institute
Home Office [UK]
Human Fertilisation and Embryology Authority (HFEA) [UK]
Human Tissue Authority (HTA) [UK]
International Consortium of Stem Cell Networks
International Society for Stem Cell Research (ISSCR)
International Stem Cell Corp
iPS Academia Japan
Israel Stem Cell Society
Keele University
Korea Stem Cell Bank
Life R.F.
LifeCell International
Lifeline Cell Technology
Maxim Biotech
Medical College of Georgia
Medical Research Council [UK]
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Medipost Co
MediStem Laboratories
Miltenyi Biotec
Ministero della Salute [Italy]
Ministry of Education, Culture, Sports, Science and Technology [Japan]
Ministry of Health [China]
Ministry of Science and Technology [China]
Minneapolis Heart Institute
MultiCell Technologies
Musculoskeletal Transplant Foundation [US]
National Center for Cell Science [India]
National Health Service (NHS) [UK]
National Heart, Lung and Blood Institute [US]
National Institutes of Health (NIH) [US]
National Marrow Donor Program [US]
National Multiple Sclerosis Society [US]
New York Stem Cell Foundation
Nippon Zoki Pharmaceutical
Northwestern University
Novo Nordisk
Oklahoma State House
OncoMed Pharmaceuticals
Opexa Therapeutics
Osiris Therapeutics
Oxford University
Parkinson's UK
Pfizer Regenerative Medicine
Pluristem Therapeutics
Progenitor Cell Therapy
Regenerative Sciences
Reliance Life Sciences
Robert Jones and Agnes Hunt Orthopaedic Hospital
RTI Biologics
Rutgers University
Saneron CCEL Therapeutics
Seoul National University
Spanish Stem Cell Bank
Stanford University
Stem Cell Innovations
Stem Cell Therapeutics
Stempeutics Research Malaysia
SUNY Upstate Medical University
Suzhou Neuralstem Biopharmaceutical Company
TCA Cellular Therapy
Thermo Fisher Scientific
Tissue Bank Cryo Center Bulgaria
UK Stem Cell Bank
University College London (UCL)
University of California
University of Edinburgh
University of Helsinki
University of Kyoto
University of Malaya
University of Massachusetts
University of Michigan
University of Modena Centre for Regenerative Health
University of Pittsburgh
University of Tübingen
University of Wisconsin
US Army Institute of Surgical Research
US Supreme Court
Vaxon Biotech
ViaCyte (formerly Novocell)
Vitro Biopharma
Voss Laboratories
Wake Forest University
Walter and Eliza Institute of Medical Research [Australia]
Weihei Municipal Price Bureau [China]
Wisconsin Alumni Research Foundation (WARF)
XCell Center
Zhejiang Lukou Biotechnology Co

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.